Newsroom | 5405 results
Sorted by: Latest
-
Wisp Names Jennifer Peña as Chief Medical Officer to Support Integrated Women’s Telehealth
NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to more than 1.5 million customers, today announced the appointment of Jennifer Peña, MD, as the company’s Chief Medical Officer. Dr. Peña will have a crucial role in driving Wisp’s commitment to being the one-stop-shop for all women’s health needs, as the company continues to scale new and existing offerings. As CMO, Dr. Peña will spearhead...
-
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib...
-
AndHealth Dermatology Welcomes Dr. Drew Kurtzman to Its Practice in Kentucky and Ohio
COLUMBUS, Ohio--(BUSINESS WIRE)--AndHealth Dermatology has welcomed Dr. Drew Kurtzman to its practice starting in May 2025. Dr. Kurtzman is a renowned board-certified dermatologist from Kentucky who will now see patients in Kentucky and Ohio as a part of AndHealth Dermatology. Appointments can be scheduled by calling 614-398-0582, by emailing appointments@andhealth.com, or by visiting DrDrewKurtzmanDermatologist.com. Dr. Kurtzman brings a deep commitment to providing compassionate, expert care...
-
The Cannabist Company Announces Director Appointments
CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., is pleased to announce the appointment of independent directors, Tom Lynch and Peter Lee, to its Board of Directors effective today, in accordance with the terms of the Amended and Restated Indenture dated May 29, 2025, entered into in connection wi...
-
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p....
-
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform...
-
Rimkus Welcomes Dr. Gavin Huntley-Fenner and Team to Enhance Human Factors Expertise
HOUSTON--(BUSINESS WIRE)--Rimkus, a premier global provider of engineering, technical consulting, and life sciences services, announced today the strategic acquisition of Huntley-Fenner Advisors Inc., led by Dr. Gavin Huntley-Fenner. The move is an expansion of the Rimkus Life Sciences group with nationally recognized talent, bringing three well recognized and highly skilled human factors experts to the Company’s Life Sciences team. Dr. Huntley-Fenner, a renowned Human Factors leader, brings a...
-
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder (“GAD”). The p...
-
Growve Secures Majority Equity Investment led by Palm Beach Capital and Debt Financing from TCW and NMP Capital
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Growve, a leader in the health and wellness industry, announced today that it has secured a majority equity investment led by Palm Beach Capital (PBC), with participation from G-Bar Ventures and NMP Capital. As part of the transaction, Growve also closed on new debt financing from TCW Private Credit and NMP Capital to support its continued growth and strategic initiatives. Growve is a $400+ million revenue health and wellness company specializing in vitami...
-
MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits
DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits. These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024...